科研之友
微信
新浪微博
Facebook
分享链接
摘要
<jats:p>Proteasome inhibition has proven to be a successful therapeutic strategy in B-cell malignancies including WM. In this issue of Blood, Roccaro and colleagues report preclinical studies, providing the rationale for clinical investigation of a novel orally available proteasome inhibitor in this disease.1</jats:p>
- 出版日期2010-5-20
